Free Newsletter
Baylor inks anti-cancer vax development pact
Japan-based SBI Biotech and Baylor Research Institute have inked a licensing deal and development agreement to develop anti-cancer vaccines for Asian markets, which could possibly include Japan, Taiwan and Korea.
The licensing agreement allows SBI to conduct clinical trials on early-stage cancer patients using Baylor's "dentritic cell immunotherapy"--a treatment designed to work in conjunction with others, such as radiation and chemotherapy. Over the past five years, the Dallas-based institute's clinical trials have only included about 100 cancer patients, all of whom have had late-stage cancer and declining immune systems.
Under the terms of the agreement, SBI will pay Baylor about $3 million in acceleration fees and another $3 million in SBI stock, with potential milestone and royalty fees that could reach a half-million.
- check out the Dallas Business Journal for more
Related Articles:
Research (and marketing) heads to Asia
Asia offers big discounts to drug developers (Mar 2006)
Taiwan to invest $1B in biotech development (July 2007)
Korea blueprints $14.3B biotech investment plan (Nov 2006)
Comments
Very interesting news I think. Well I always follow your website because it is full of the useful information about various subjects. Our world is developing rapidly so it is not a surprise that doctors and other specialized people more and more use software applications in the medicine. And I am so happy of it that we have such modern technologies which other people have not have before 50 years. Thanks a lot one more time for the great post and I will be waiting for more news form you in the future.
Sincerely, Jeremy Watson from custom software development
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




